Accelerating access to psychedelic-based medicines for patients with urgent and unmet needs. VANCOUVER, BC, Jan. 4, 2022 /CNW/ – On the 17th December 2021 the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) produced guidance acknowledging and setting out the criteria for the use of Real World Data and Evidence in regulatory decision making. This guidance is consistent with Albert…


Previous articlePsychedelic Bulletin: First Look at Field Trip’s FT-104 Molecule; MindMed Trial Halted by FDA, Changes at the Top
Next articlePT281 – Oliver Grundmann, Ph.D. – A Thorough Exploration of Kratom